enzh-TWfrdeitjaptrues

Date: March 12, 2011 Location: 4th International Patient & Physician Summit on WM, Orlando, FL
Lecturer: Tricia Sheehy, NP, Bing Center for WM Subject: Peripheral Neuropathy in WM

Click video player to start video. NOTE: It may take a few minutes for video to load. Use the navigation controls in the PDF viewer to view the corresponding slide in the lecture.

Latest Bing Center News

Ibrutinib Demonstrates Long-Term Safety, Activity in Relapsed/Refractory WM

Ibrutinib Demonstrates Long-Term Safety, Activity in Relapsed/Refractory WM

Ibrutinib is a highly active and tolerable therapy for symptomatic, relapsed, or refractory patients with Waldenström macroglobulinemia (WM) and a preferable option for use in previously treated patients, according to a study published in the Journal of Clinical Oncology (2020;JCO2000555. doi:10.1200/JCO.20.00555).

Read more..

The fourth issue of the 21st volume of the IWMF Torch is now online!

The fourth issue of the 21st volume of the IWMF Torch is now online!

If you’ve ever had questions about clinical trials, this issue will help clarify various aspects of them, from both the doctor’s and the patient’s perspectives. It will be obvious that medical as well as personal reasons need to be considered before making the plunge.

Read more..

BTK Inhibitors Transform Waldenström Macroglobulinemia Management

BTK Inhibitors Transform Waldenström Macroglobulinemia Management

BTK inhibitors have transformed the treatment of patients with Waldenström macroglobulinemi; with 4 agents under examination in the space, selection will depend on availability, toxicity, convenience, and cost.

Read more..

IWMF Renews Funding for Pivotal WM Research Project with Dr. Steve Treon

IWMF Renews Funding for Pivotal WM Research Project with Dr. Steve Treon

The International Waldenstrom's Macroglobulinemia Foundation (IWMF) Board of Trustees has reviewed and approved funding an additional $500,000 to renew Dr. Steve Treon's legacy research project.

Read more..

Making Sense of the Science of WM with Dr. Zachary Hunter

Making Sense of the Science of WM with Dr. Zachary Hunter

Making Sense of the Science of WM sets out a framework for patients to understand the basic genetic concepts behind the mutations that are important in WM, to appreciate the ways in which these mutations impact the signaling systems that control the behavior of WM cells, and to recognize how these mutations are changing the landscape of therapies for WM.

Read more..

Steven P. Treon, MD, PhD, on Treating COVID-19–Related Pulmonary Failure by Targeting BTK With Ibrutinib

Steven P. Treon, MD, PhD, on Treating COVID-19–Related Pulmonary Failure by Targeting BTK With Ibrutinib

Steven P. Treon, MD, PhD, of Dana-Farber Cancer Institute, discusses Bruton’s tyrosine kinase (BTK), which is activated during severe COVID-19 infection. Patients with the coronavirus and chronic lymphocytic leukemia who remained on the BTK inhibitor ibrutinib had a mild disease course, with decreased C-reactive protein and improved oxygenation. Clinical trials to validate the role of BTK inhibitors in treating COVID-19–related pulmonary distress are now underway.

Read more..

Next Generation BTK-Inhibitors in Waldenstrom's Macroglobulinemia

Next Generation BTK-Inhibitors in Waldenstrom's Macroglobulinemia

Dr. Steven Treon delivered this on-line lecture on August 5, 2020 for the benefit of the WMFC Toronto Support Group. It is our privilige to share it with the entire WM community.  It focuses on the role of BTK Inhibitors in the treatment of Waldenstrom's Macroglobulinemia, and the advances being made based on the latest research.

Read more..

2020 IWMF GLOBAL EDUCATIONAL WEBINAR: Getting to Know WM: Basics & Beyond with Dr. Jeffrey Matous

2020 IWMF GLOBAL EDUCATIONAL WEBINAR: Getting to Know WM: Basics & Beyond with Dr. Jeffrey Matous

The International Waldenstrom's Macroglobulinemia Foundation invites you to join us for the first installment in our 2020 IWMF Global Educational Webinar series.

Read more..

Waldenstrom Patient Stories: Finding Strength

Waldenstrom Patient Stories: Finding Strength

When Peter DeNardis was diagnosed with Waldenstrom macroglobulinema (WM) 17 years ago, all he knew was that he had an incurable cancer. He had never heard of this rare type of non-Hodgkin lymphoma. A married father of three in his early 40s, DeNardis worried about how his illness would impact his family. How would his passing affect them emotionally and financially?

Read more..

Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic

Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic

In the light of the COVID-19 pandemic, the International Workshop on Waldenström Macroglobulinemia (IWWM) Treatment Recommendations Panel felt the need to provide a consensus statement for the management of Waldenström Macroglobulinemia (WM) patients during this challenging time.

Read more..